Autologous hematopoietic stem cell transplantation as first‐line consolidation therapy can improve the prognosis of diffuse large B‐cell lymphoma with high expression of MYC protein

Abstract

Myc‐positive diffuse large B‐cell lymphoma has lower curative efficacy and long‐term survival than its negative counterpart, even when treated with R‐CHOP regimen. The present study aims to determine whether the use of autologous hematopoietic stem cell transplantation as a consolidation therapy can improve the curative efficacy in this type of patients after achieving the best effect of chemotherapy for the first time. The data of 50 patients with Myc‐positive diffuse large B‐cell lymphoma were retrospectively analyzed. Autologous transplantation was performed for 23 patients, while transplantation was not performed for 27 patients. The clinicopathological features and survival conditions were compared. The 1‐year and 3‐year progression‐free survival (PFS) rates were 66.7% ± 0.9% and 57.7% ± 1.0%, respectively, in the non transplantation group, and 100% and 82.1% ± 0.1%, respectively, in the transplantation group (P = .021). The 1‐year overall survival (OS) rate for these two groups was 88.7% ± 0.6% vs 100%, respectively, while the 3‐year OS rates for these two groups was 78.6% ± 0.1% vs 91.3% ± 0.1%, respectively (P = .176). Hematopoietic stem cell transplantation performed after chemotherapy is a risk factor for OS. Autologous hematopoietic stem cell transplantation as a consolidation therapy in the early stage can improve the prognosis of patients with Myc‐positive diffuse large B‐cell lymphoma.

Primary breast double-hit lymphoma management and outcomes: a real-world multicentre experience

“…High-dose chemotherapy followed by ASCT in an upfront setting currently remains the second-line treatment for DLBCL [ 35 ], and ASCT is the only feasible therapy offering a cure. Due to the limited efficacy of conventional chemotherapy, dynamic dose-adjusted chemotherapy supported by ASCT should be administered to young PB-DBL patients [ 36 , 37 ]. The ASCT results showed excellent efficacy and durable remission among patients with CR in a pre-transplantation setting, which is an important initial step for developing ASCT as a first-line treatment strategy for highly aggressive PB-DHL.…”